A few months af­ter emerg­ing from stealth, Prax­is is hand­ed a clin­i­cal hold for lead de­pres­sion drug

Less than a month af­ter Prax­is Pre­ci­sion Med­i­cines hit Wall Street with an up­sized IPO, the FDA has slapped a clin­i­cal hold on its lead can­di­date for ma­jor de­pres­sive dis­or­der (MDD), send­ing shares spi­ral­ing.

With­out pro­vid­ing much in­for­ma­tion, the FDA said in an email that it re­viewed Prax­is’ IND for its Phase II/III tri­al, and is plac­ing a full clin­i­cal hold on the study. More de­tails should come in the next 30 days, ac­cord­ing to the email. Prax­is says it has reached out to the agency, which said it isn’t done fi­nal­iz­ing com­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA